Lavino Francesco Maria 4
4 · Nabriva Therapeutics plc · Filed Aug 21, 2019
Insider Transaction Report
Form 4
Lavino Francesco Maria
Chief Commercial Officer
Transactions
- Tax Payment
Ordinary Shares
2019-08-21$2.08/sh−3,797$7,898→ 11,172 total - Exercise/Conversion
Restricted Share Units
2019-08-19−11,250→ 11,250 total→ Ordinary Shares (11,250 underlying) - Exercise/Conversion
Ordinary Shares
2019-08-19+11,250→ 14,969 total
Footnotes (2)
- [F1]The restricted share units convert into ordinary shares on a one-for-one basis upon vesting of the units.
- [F2]On January 31, 2018, Nabriva Therapeutics plc (the "Issuer") granted the reporting person 22,500 restricted share units ("RSUs"). Fifty percent (50%) of the RSUs vested on August 19, 2019 upon certifcation by the board of directors of the Issuer of the receipt by the Issuer of approval of a new drug application by the U.S. Food and Drug Administration for lefamulin (the "Performance Condition"), and the remaining fifty percent (50%) of the RSUs will vest on the one (1) year anniversary of the Performance Condition.